StockNow
Log in
U.S. Markets

Boston Scientific (BSX) Q2 2026 (USD): EPS 0.86 (exp. 0.83), Revenue 5.44bln (exp. 5.37bln); FY adj. EPS view 3.28-3.32 (exp. 3.36)

StockNow breaking-news AI analysis

BSX beat Q2 earnings and revenue expectations but issued conservative FY guidance below consensus, overshadowed by a major $800M restructuring plan aimed at long-term cost efficiency amidst rising competition.

News detail

Q3 adj. EPS view 0.80-0.82 (exp. 0.84).

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Pakistani sources say Pakistan PM Sharif and Army Chief Munir will visit Saudi Arabia tomorrow, Al Hadath reports

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)